公司近期披露2025年半年度报告显示，上半年实现营业收入1.5亿元，同比增长2.16%；归母净利润 1104.58万元，同比增长5.94%；扣非净利润680.64万元，同比增长158.29%。公司董事会和监事会已审 议通过半年度报告及相关议案。 风险提示：本文不构成任何投资建议，投资者应自主决策并承担相应风险。 来源：金融界 中科美菱最新股价报21.98元，较前一交易日上涨2.47%。盘中最高触及21.98元，最低下探21.33元，成 交量为24140手，成交金额达0.52亿元。 中科美菱属于专用设备制造业，是国家级专精特新"小巨人"企业。公司专注于生物医疗低温存储设备研 发制造，产品涵盖-180℃至8℃全温区存储设备、液氮容器等，为医疗、科研等领域提供解决方案。公 司2025年上半年实现营业收入1.5亿元，归母净利润1104.58万元。 ...

Company Overview - Haier Biomedical focuses on the research, production, and sales of biomedical low-temperature storage equipment, providing digital scene solutions in life sciences and medical innovation [2] - The company serves a wide range of users, including hospitals, biopharmaceutical companies, research institutions, disease control centers, and blood stations, offering comprehensive solutions centered around smart laboratories and digital hospitals [2] - Haier Biomedical has established partnerships with over 40 international organizations, including WHO and UNICEF, and its products are applied in more than 130 countries and regions globally [2] Financial Performance - As of the latest quarterly report for 2024, the company achieved a revenue of 1.782 billion yuan, a year-on-year decrease of 2.43%, and a net profit of 309 million yuan, down 13.45% year-on-year, with a gross profit margin of 48.51% [2] - The company's stock closed at 33.78 yuan, with a rolling price-to-earnings (PE) ratio of 29.29 times and a total market capitalization of 10.740 billion yuan [1] Industry Comparison - The average PE ratio for the medical device industry is 44.91 times, with a median of 31.89 times, positioning Haier Biomedical at the 69th rank within the industry [1][3] - The company has a lower PE ratio compared to the industry average, indicating potential undervaluation relative to its peers [3] Shareholder Information - As of September 30, 2024, Haier Biomedical had 12,200 shareholders, an increase of 1,510 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1]